Edwards Lifesciences
201
24
56
101
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
9.0%
18 terminated/withdrawn out of 201 trials
84.9%
-1.6% vs industry average
1%
3 trials in Phase 3/4
55%
56 of 101 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (201)
The Continuity Study
Role: lead
SAPIEN 3 Ultra System PMCF
Role: lead
Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
Role: lead
Edwards EVOQUE Eos MISCEND Study
Role: lead
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
Role: lead
ClearSight NextGen1 Study
Role: lead
Real World Data Collection on the INSPIRIS RESILIA Aortic Valve
Role: lead
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
Role: lead
The EASE-IT CT Registry
Role: collaborator
INSPIRIS China PMCF Study
Role: lead
Continuous Assessment of Brain Blood Perfusion in Subarachnoid Hemorrhage Patients Using Near-Infrared Spectroscopy (NIRS)
Role: collaborator
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
Role: lead
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
Role: lead
TRISCEND II Pivotal Trial
Role: lead
The ENCIRCLE Trial
Role: lead
Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion
Role: collaborator
The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study
Role: lead
COMPASSION S3 Post-Approval Study
Role: lead
TVMR With the INNOVALVE System Trial - Early Feasibility Study
Role: lead
Exploratory Study of the Edwards APTURE Transcatheter Shunt System (ALT-FLOW Canada)
Role: lead